首页> 外国专利> New pyrrole derivatives are cannabinoid receptor antagonists useful to prevent/treat psychiatric disorders, cognitive disorders, neurodegenerative diseases, metabolic disorders, dyslipidemia, pain, ulcer and tobacco weaning

New pyrrole derivatives are cannabinoid receptor antagonists useful to prevent/treat psychiatric disorders, cognitive disorders, neurodegenerative diseases, metabolic disorders, dyslipidemia, pain, ulcer and tobacco weaning

机译:新的吡咯衍生物是大麻素受体拮抗剂,可用于预防/治疗精神疾病,认知障碍,神经退行性疾病,代谢障碍,血脂异常,疼痛,溃疡和烟草断奶

摘要

Pyrrole derivatives (I), in the form of base or acid addition salts, hydrates or solvates, are new. Pyrrole derivatives of formula (I), in the form of base or acid addition salts, hydrates or solvates, are new. A : 1-6C alkylene (optionally substituted by 1-3C alkyl) or a phenyl moiety of formula (Iz); m : 0-2; p : 0-1; either R 1H or 1-4C alkyl; R 23-10C alkyl (optionally substituted by CF 3), 3-12C non-aromatic carbocyclic (optionally substituted by 1-4C alkyl, OH, CN, 1-4C alkoxy or -COR 12), indanyl, 1,2,3,4-tetrahydronaphtalenyl -1 or -2, 5-7 membered mono-oxygenated or mono-sulfidized heterocyclic (optionally substituted by 1-4C alkyl), 5-7 membered mono-nitrogenized heterocyclic (optionally substituted by 1-4C alkyl, the nitrogen atom is substituted by 1-4C alkyl, 1-4C alkoxycarbonyl, 1-4C alkanoyl or phenyl or benzyl( both optionally substituted by halo, 1-4C alkyl, CF 3, OH or 1-4C alkoxy), benzothiophenyl or indolyl (both optionally substituted by 1-4C alkyl), 1-3C alkylene carrying 3-10C non-aromatic carbocyclic radical (optionally substituted by 1-4C alkyl, OH, 1-4C alkoxy, CN, or -COR 12), 1-3C alkylene carrying a 5-7 membered hetero(aromatic)cyclic radical (optionally substituted by 1-4C alkyl), 1-3C alkylene (optionally substituted by OH, Me or OMe, or -COR 12) carrying an indolyl or a benzothiophenyl radical (optionally substituted by 1-4C alkyl), 1-3C alkylene carrying 1-4C alkylthio group), phenyl-1-3C alkylene (optionally substituted on alkylene by Me, OH, hydroxymethyl, OMe, methoxymethyl or COR 12, and optionally substituted on the phenyl by halo or 1-4C alkyl, CF 3, 1-4C alkoxy or CF 3), benzydryl or benzydrylmethyl or NR 10R 11; or NR 1R 2morpholinyl, piperazin-1-yl or 1,4-diazepan-1-yl (optionally substituted by phenyl, benzyl, benzodioxolyl, benzodioxolylmethyl, tetrahydrofuranylcarbonyl or COR 12 or -CH 2COR 12), piperidin-1-yl or pyrrolidin-1-yl (optionally mono or gem disubstituted by F, or phenyl, benzyl, piperidin-1-yl, pyrrolidin-1-yl, 1-4C alkyl, OH, CN or COR 12, -NR 13R 14, -NHCOR 15, -CH 2COR 12, -SO 2-Alk or -SO 2-NR 13R 14, where phenyl and benzyl are optionally substituted by halo, Me, -CF 3, hydrolyl or 1-4C alkoxy); R 3-R 8H or halo, 1-5C alkoxy, S(O) n-Alk2, -OS(O) n-Alk2 or 1-7C alkyl (optionally substituted by F, O-Alk2, S(O) nAlk2 or OS(O) nAlk); R 9OH, CN, -COOH, -NR 13R 14, -CONR 13R 14, -CONHNH 2, -CONHOH, -CONHSO 2-Alk, -S(O) n-Alk, -SO 2CF 3, -SO 2-NR 13R 14, -NHSO 2-Alk, -NHSO 2CF 3, -NH-SO 2-NR 13R 14 or 3-hydroxy-3H-imidazole-4-yl, 1H-tetrazol-5-yl, 3-hydroxy-1H-pyrazol-5-yl, 3-hydroxy-isoxazol-5-yl, 3-hydroxy-isothiazol-5-yl, 2-oxo-2,3-dihydro-2lambda-4-[1,2,3,5]oxathiadiazole-4-yl, 5-hydroxy-isoxazole-4-yl or 2-Hydroxy-2H-pyrazole-3-yl; either R 10H or Me; R 113-6C alkyl, phenyl or 3-10C cycloalkyl, where the phenyl and 3-10C cycloalkyl are optionally substituted by halo, 1-4C alkyl or -CF 3; or NR 10R 114-11 membered heterocyclic radical optionally comprising a spirannic carbon and optionally containing a second heteroatom of O or N, optionally substituted by OH, 1-4C alkyl, 1-4C alkoxycarbonyl or phenyl (optionally substituted by halo or 1-4C alkyl); R 121-4C alkyl, phenyl, benzyl, 1-4C alkoxy, CF 3 or NR 13R 14; either R 13, R 14H or 1-4C alkyl; NR 13R 144-7 membered heterocyclic (optionally containing second heteroatom N, O or S); R 15-14C alkyl or CF 3; n : 0-2; Alk2 : 1-4C alkyl (optionally substituted by F); and Alk : 1-4C alkyl. Independent claims are included for: (1) the preparation of (I); and (2) a pyrrole derivative of formula (IIa). X : halo, OH, 1-4C alkoxy or benzyloxy. [Image] [Image] [Image] ACTIVITY : Neuroleptic; Nootropic; Tranquilizer; Neuroprotective; Metabolic; Anorectic; Antidiabetic; Analgesic; Antianginal; Antilipemic; Gastrointestinal-Gen; Antiemetic; Antidiarrheic; Antiulcer; Hepatotropic; Immunomodulator; Antiarthritic; Antirheumatic; Antiinflammatory; Antiparkinsonian; Antismoking; Antidepressant; Hypnotic; Antialcoholic; Antimigraine; Anticonvulsant; Muscular-Gen.; Inotropic; Vasotropic; Cerebroprotective; Antiaddictive; Eating-Disorders-Gen; Cardiovascular-Gen; Uropathic; Virucide; Endocrine-Gen; Hypertensive; Antiarteriosclerotic; Antibacterial; Immunosuppressive; Antiasthmatic; Respiratory-Gen; Ophthalmological; Antiinfertility; Gynecological; CNS-Gen; Osteopathic. MECHANISM OF ACTION : Cannabinoid CB 1 receptor antagonist.
机译:呈碱或酸加成盐,水合物或溶剂化物形式的吡咯衍生物(I)是新的。呈碱或酸加成盐,水合物或溶剂合物形式的式(I)的吡咯衍生物是新的。 A:1-6C亚烷基(任选地被1-3C烷基取代)或式(Iz)的苯基部分; m:0-2; p:0-1; R 1H或1-4C烷基; R 23-10C烷基(可选被CF 3取代),3-12C非芳族碳环(可选被1-4C烷基,OH,CN,1-4C烷氧基或-COR 12取代),茚满基,1,2,3 ,4-四氢萘-1或-2、5-7元单氧或单硫化的杂环(可选被1-4C烷基取代),5-7元单氮化的杂环(可选被1-4C烷基取代),氮原子被1-4C烷基,1-4C烷氧基羰基,1-4C烷酰基或苯基或苄基(均可选地被卤素,1-4C烷基,CF 3,OH或1-4C烷氧基取代),苯甲硫基苯基或吲哚基(均被1-4C烷基取代),带有3-10C非芳族碳环基的1-3C亚烷基(可选被1-4C烷基,OH,1-4C烷氧基,CN或-COR 12取代),1-3C带有5-7元杂(芳)环基团的亚烷基(可选地被1-4C烷基取代),带有吲哚基或苯甲硫基苯基的1-3C亚烷基(可选地被OH,Me或OMe或-COR 12取代)(运(通常被1-4C烷基取代),带有1-4C烷硫基的1-3C亚烷基),苯基-1-3C亚烷基(可选地在Meth上被Me,OH,羟甲基,OMe,甲氧基甲基或COR 12取代,并可选地在苯基是卤素或1-4C烷基,CF 3,1-4C烷氧基或CF 3),苄基或苄基甲基或NR 10R 11;或NR 1R 2吗啉基,哌嗪-1-基或1,4-二氮杂-1-基(可选被苯基,苄基,苯并二恶唑基,苯并二恶唑基甲基,四氢呋喃基羰基或COR 12或-CH 2COR 12取代),哌啶-1-基或吡咯烷基-1-基(可选被F或苯基,苄基,哌啶-1-基,吡咯烷-1-基,1-4C烷基,OH,CN或COR 12取代的单或双宝石,-NR 13R 14,-NHCOR 15 ; -CH 2COR 12,-SO 2-烷基或-SO 2 -NR 13R 14,其中苯基和苄基任选地被卤素,Me,-CF 3,水解基或1-4C烷氧基取代); R 3-R 8H或卤素,1-5C烷氧基,S(O)n-Alk2,-OS(O)n-Alk2或1-7C烷基(可选被F,O-Alk2,S(O)nAlk2或OS(O)nAlk); R 9OH,CN,-COOH,-NR 13R 14,-CONR 13R 14,-CONHNH 2,-CONHOH,-CONHSO 2-烷基,-S(O)n-烷基,-SO 2CF 3,-SO 2-NR 13R 14 --NHSO 2-烷基,-NHSO 2CF 3,-NH-SO 2-NR 13R 14或3-羟基-3H-咪唑-4-基,1H-四唑-5-基,3-羟基-1H-吡唑-5-基,3-羟基-异恶唑-5-基,3-羟基-异噻唑-5-基,2-氧代-2,3-二氢-2lambda-4- [1,2,3,5]恶二唑-4-基,5-羟基-异恶唑-4-基或2-羟基-2H-吡唑-3-基; R 10H或Me; R 113-6C烷基,苯基或3-10C环烷基,其中苯基和3-10C环烷基任选地被卤素,1-4C烷基或-CF 3取代;或NR 10R 114-11元杂环基,其任选地包含螺碳原子碳并任选地包含O或N的第二杂原子,其任选地被OH,1-4C烷基,1-4C烷氧羰基或苯基取代(可选地被卤素或1-4C取代)烷基); R 121-4C烷基,苯基,苄基,1-4C烷氧基,CF 3或NR 13R 14; R 13,R 14H或1-4C烷基; NR 13R 144-7元杂环(任选地包含第二杂原子N,O或S); R 15-14C烷基或CF 3; n:0-2; Alk 2:1-4C烷基(任选地被F取代); Alk:1-4C烷基。独立索赔包括:(1)(I)的制备; (2)式(IIa)的吡咯衍生物。 X:卤素,OH,1-4C烷氧基或苄氧基。 [图像] [图像] [图像]活动:精神安定药;促智;镇静剂;具有神经保护作用;新陈代谢;厌食的;抗糖尿病止痛药抗心绞痛抗血脂;胃肠源;止吐药;止泻药抗溃疡;肝免疫调节剂抗关节炎抗风湿;消炎(药;反帕金森病;禁止吸烟;抗抑郁药催眠;抗酒;抗偏头痛;抗惊厥药;肌肉型;变力;变压性脑保护反吸毒饮食失调症心血管基因尿毒症;杀病毒剂;内分泌基因高血压;抗动脉硬化;抗菌;免疫抑制抗哮喘呼吸源眼科抗不孕症;妇科CNS-Gen;整骨疗法。作用机理:大麻素CB 1受体拮抗剂。

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号